ID

33074

Description

Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella CRF Seiten: 268-336; 870-938

Keywords

Versions (2)
  1. 11/22/18 11/22/18 -
  2. 11/26/18 11/26/18 -
Copyright Holder

GSK group of companies

Uploaded on

November 26, 2018

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

No comments

In order to download data models you must be logged in. Please log in or register for free.

Immunogenicity of Combined Measles Mumps Rubella Varicella Vaccine for healthy 2 y.o children - 104020

English

Eligibility Criteria

1 forms  
  1. StudyEvent: ODM
    1. Eligibility Criteria
Administrative data
Description

Administrative data

Visit Number
Description

Visit Number

Data type

text

Date of Visit
Description

Date of Visit

Data type

date

Subject Number
Description

Subject Number

Data type

integer

Eligibility Question
Description

Eligibility Question

Did the subject meet all the entry criteria?
Description

Did the subject meet all the entry criteria?

Data type

boolean

If No, tick all boxes corresponding to violations of any exclusion/inclusion criteria
Description

Do not enter the subject into the study if he/she failed any inclusion or exclusion criteria below

Data type

text

Inclusion Criteria
Description

Inclusion Criteria

Tick the boxes corresponding to any of the inclusion criteria the subject failed
Description

Tick the boxes corresponding to any of the inclusion criteria the subject failed

Data type

text

Exclusion Criteria
Description

Exclusion Criteria

Record if any of the exclusion criteria disqualified the subject from entry
Description

tick Yes, if disqualified, tick No, if not disqualified

Data type

text

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Description

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

Data type

boolean

Chronic administration (more than 14 days) of immunodepressants or other immune-modifying drugs within six months prior to the first vaccine dose
Description

For corticosteroids this will mean prednisone, or equivalet, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed

Data type

boolean

Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)
Description

Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)

Data type

boolean

Previous vaccination against measles, mumps, rubella and/or varicella
Description

Previous vaccination against measles, mumps, rubella and/or varicella

Data type

boolean

History of measles, mumps, rubella and/or varicella/zoster diseases
Description

History of measles, mumps, rubella and/or varicella/zoster diseases

Data type

boolean

Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial
Description

Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial

Data type

boolean

Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection
Description

Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection

Data type

boolean

A family history of congenital or hereditary immunodeficiency
Description

A family history of congenital or hereditary immunodeficiency

Data type

boolean

History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
Description

History of allergic disease or reactions likely to be exacerbated by any component of the vaccine

Data type

boolean

Major congenital defects or serious chronic illness
Description

Major congenital defects or serious chronic illness

Data type

boolean

History of any neurologic disorders or seizures
Description

History of any neurologic disorders or seizures

Data type

boolean

Residence in the same household as high-risk persons
Description

high-risk persons: new-born infants (0-4 weeks of age); pregnant mother/women with a negative history of chickenpox disease and without recorded vaccination against chickenpox; persons with known immunodeficiency

Data type

boolean

Acute disease at the time of enrolment
Description

The presence of a moderate or severe illness with or without fever. All vaccines cn be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature <37.5°C/ rectal temperature <38°C.

Data type

boolean

Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination
Description

Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination

Data type

boolean

Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period
Description

Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period

Data type

boolean

Back to the top of the page

Similar models

Eligibility Criteria

1 forms
  1. StudyEvent: ODM
    1. Eligibility Criteria
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative data
Item
Visit Number
text
Visit Number
Code List
Visit Number
CL Item
Visit 1 (1)
Date of Visit
Item
Date of Visit
date
Subject Number
Item
Subject Number
integer
Item Group
Eligibility Question
Did the subject meet all the entry criteria?
Item
Did the subject meet all the entry criteria?
boolean
If No, tick all boxes corresponding to violations of any exclusion/inclusion criteria.
Item
If No, tick all boxes corresponding to violations of any exclusion/inclusion criteria
text
Item Group
Inclusion Criteria
Item
Tick the boxes corresponding to any of the inclusion criteria the subject failed
text
Tick the boxes corresponding to any of the inclusion criteria the subject failed
Code List
Tick the boxes corresponding to any of the inclusion criteria the subject failed
CL Item
Subject who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study (1)
CL Item
Male or female subject between 11 and 21 months of age at the time of the first vaccination (2)
CL Item
Written informed consent obtained from the parent or guardian of the subject (3)
CL Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study (4)
Item Group
Exclusion Criteria
Record if any of the exclusion criteria disqualified the subject from entry
Item
Record if any of the exclusion criteria disqualified the subject from entry
text
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
boolean
Chronic administration (more than 14 days) of immunodepressants or other immune-modifying drugs within six months prior to the first vaccine dose
Item
Chronic administration (more than 14 days) of immunodepressants or other immune-modifying drugs within six months prior to the first vaccine dose
boolean
Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)
Item
Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)
boolean
Previous vaccination against measles, mumps, rubella and/or varicella
Item
Previous vaccination against measles, mumps, rubella and/or varicella
boolean
History of measles, mumps, rubella and/or varicella/zoster diseases
Item
History of measles, mumps, rubella and/or varicella/zoster diseases
boolean
Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial
Item
Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial
boolean
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection
Item
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection
boolean
A family history of congenital or hereditary immunodeficiency
Item
A family history of congenital or hereditary immunodeficiency
boolean
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
boolean
Major congenital defects or serious chronic illness
Item
Major congenital defects or serious chronic illness
boolean
History of any neurologic disorders or seizures
Item
History of any neurologic disorders or seizures
boolean
Residence in the same household as high-risk persons
Item
Residence in the same household as high-risk persons
boolean
Acute disease at the time of enrolment
Item
Acute disease at the time of enrolment
boolean
Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination
Item
Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination
boolean
Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period
Item
Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period
boolean
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial